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Kallistatin limits abdominal 
aortic aneurysm by attenuating 
generation of reactive oxygen 
species and apoptosis
Smriti Murali Krishna1,6, Jiaze Li1, Yutang Wang1,2, Corey S. Moran1, Alexandra Trollope1,3, 
Pacific Huynh1, Roby Jose1, Erik Biros1, Jianxing Ma4 & Jonathan Golledge1,5,6*
Inflammation, vascular smooth muscle cell apoptosis and oxidative stress are believed to play 
important roles in abdominal aortic aneurysm (AAA) pathogenesis. Human kallistatin (KAL; gene 
SERPINA4) is a serine proteinase inhibitor previously shown to inhibit inflammation, apoptosis and 
oxidative stress. The aim of this study was to investigate the role of KAL in AAA through studies in 
experimental mouse models and patients. Serum KAL concentration was negatively associated with 
the diagnosis and growth of human AAA. Transgenic overexpression of the human KAL gene (KS-
Tg) or administration of recombinant human KAL (rhKAL) inhibited AAA in the calcium phosphate 
 (CaPO4) and subcutaneous angiotensin II (AngII) infusion mouse models. Upregulation of KAL in 
both models resulted in reduction in the severity of aortic elastin degradation, reduced markers 
of oxidative stress and less vascular smooth muscle apoptosis within the aorta. Administration of 
rhKAL to vascular smooth muscle cells incubated in the presence of AngII or in human AAA thrombus-
conditioned media reduced apoptosis and downregulated markers of oxidative stress. These effects of 
KAL were associated with upregulation of Sirtuin 1 activity within the aortas of both KS-Tg mice and 
rodents receiving rhKAL. These results suggest KAL-Sirtuin 1 signalling limits aortic wall remodelling 
and aneurysm development through reductions in oxidative stress and vascular smooth muscle cell 
apoptosis. Upregulating KAL may be a novel therapeutic strategy for AAA.
Abdominal aortic aneurysm (AAA) is an important cause of  mortality1. Current guidelines recommend surgical 
repair of large (maximum aortic diameter ≥ 55 mm in men and ≥ 50 mm in women) asymptomatic or sympto-
matic AAAs and imaging surveillance alone for small asymptomatic AAAs (< 55 mm in men and < 50 mm in 
women)2. The increasing use of abdominal imaging and ultrasound screening programs means that many AAAs 
are identified when they are small and  asymptomatic3. Up to 70% of small AAAs grow to a size at which surgical 
repair is  indicated4,5. The discovery of drug therapies effective in limiting AAA growth would markedly change 
current patient  management5–8.
Human kallistatin (KAL; gene SERPINA4) is a member of the serine proteinase inhibitor  superfamily9. KAL 
is expressed in circulating and aortic cells including vascular smooth muscle cells (VSMCs) and therefore could 
theoretically play a protective role against human AAA formation and  progression10. Recent research suggests 
that the Wingless integrated (Wnt) pathway promotes AAA pathogenesis, while the Sirtuin 1 (SIRT1) pathway 
inhibits AAA  formation11,12. KAL has been reported to be an endogenous inhibitor of the Wnt pathway and to 
activate the SIRT1  pathway13,14. Furthermore, previous animal and in vitro studies suggest that KAL inhibits 
reactive oxygen species (ROS) formation and limits inflammation and extracellular matrix (ECM) remodelling 
and blocks cellular apoptosis, which are all implicated in AAA  pathogenesis8. Recent research also suggests that 
KAL inhibits atherosclerosis development in dyslipidemic  mice15.
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In view of this previous research, it was hypothesised that KAL would inhibit AAA pathogenesis. This theory 
was studied using patient samples and mouse models. Specifically it was hypothesised that circulating concentra-
tions of KAL would be negatively associated with human AAA diagnosis and growth. It was also hypothesised 
that upregulation of KAL would reduce the severity of AAA in two mouse models of AAA.
Methods
Study design. This study was designed to carry out the following aims: (1) to examine the association of 
circulating KAL concentrations with AAA diagnosis and growth in patients; (2) to examine the effect of admin-
istering recombinant human (rhKAL) on AAA development in a mouse model; (3) to examine the effect of 
rhKAL on human aortic VSMCs in vitro and (4) to examine the effect of overexpressing human KAL on AAA 
development within a mouse model.
Human blood and tissue samples. Serum samples were obtained from men involved in the Health in 
Men Study (HIMS), which has been previously described in  detail16. Community-dwelling men (n = 12,203) 
aged 65–83 years took part in a randomised trial of ultrasound screening for AAA. Each man had an abdominal 
ultrasound between 1996 and 1999 (HIMS wave 1). In 2001–2004, (HIMS wave 2) blood samples were collected 
from 4249 of the men. For the current study, men (n = 304) who were found to have an AAA on ultrasound [infra-
renal aortic diameter (IRA) ≥ 30 mm] and which serum samples were available were included. We randomly 
selected approximately twice as many men (n = 652) in which no AAA was identified (IRA diameter < 30 mm) as 
controls. The Human Research Ethics Committee of the University of Western Australia approved the protocol 
for HIMS (RA/4/1/5765) and all men provided written informed consent.
A further group of patients with large AAAs undergoing open repair were recruited from Townsville Uni-
versity Hospital, Australia. Full thickness samples were obtained from the anterior wall of the aneurysm body 
(site of maximum aortic dilation; AAA-Body, n = 12) and macroscopically non-dilated proximal neck of aneu-
rysm (site immediately distal to the renal arteries where the aortic diameter was relatively normal; AAA-Neck, 
n = 6) using procedures previously  described17. The study was approved by the Human Ethics Committees of 
the Townsville Hospital and Health Services and James Cook University (HREC/12/QTHS/202). All protocols 
conformed to the ethical guidelines of the Declaration of Helsinki and samples were obtained after receiving 
written informed consent.
Risk factors. These were collected by assessment of medical records and interview. Waist and hip circum-
ference were measured in accordance with guidelines of the International Society for the Advancement of 
 Kinanthropometry18. Diabetes and hypertension were defined by a history of diagnosis or treatment of these 
conditions. Coronary heart disease (CHD) was defined by a history of myocardial infarction, angina or treat-
ment for coronary artery disease. Previous stroke was defined by a previous history of any stroke. Smoking was 
defined by history as ever having smoked regularly or never having smoked regularly. Prescribed medications 
were also recorded.
Aortic imaging. Aortic ultrasound was performed as previously  described16. The greatest diameter of the 
IRA was measured from the outer to the outer wall of the aorta using a Toshiba Capasee ultrasound machine 
with a 3.75 MHz probe (Toshiba Australia, North Ryde, NSW)19. In participants in which a small AAA was 
detected, repeat aortic imaging was recommended at intervals of 6 months if the initial diameter was ≥ 40 mm 
and 12  months if the initial diameter was 30–39  mm. The reproducibility of ultrasound measurements was 
assessed every 4 months by repeat scanning of 10 randomly selected participants on two occasions by the three 
different sonographers. No significant differences were found between observers, with 95% of differences in each 
of antero-posterior and transverse diameters being < 3  mm19.
Blood assays. Serum KAL was measured with a commercial assay (R&D Systems, Minneapolis, USA) by 
an experienced scientist. The inter-assay coefficient of variation was 5%. Serum creatinine, low density lipo-
protein (LDL) and high density lipoprotein (HDL) were measured using automated assays (Hitachi 917, Roche 
Diagnostics GmBH, Mannheim, Germany), as previously  described20. The inter-assay coefficient of variation 
for these assays was between 2 and 5%. Serum high sensitivity C-reactive protein (hs-CRP) was measured by a 
high-sensitivity assay, with the use of the particle-enhanced immunonephelometry system on the BNII analyser. 
The inter-assay coefficient of variation was 4–7% (Dade Behring)19.
Mouse models and in vivo studies. The mouse studies were performed in accordance with institutional 
and ethical guidelines of James Cook University, Australia. The experimental protocols were in accordance 
with the ARRIVE guidelines and were approved by the James Cook University animal ethics committee (AEC 
approval A2125). All animal protocols conformed to the Guide for the Care and use of Laboratory Animals 
(National Institutes of Health, United States) and the Australian Code of Practice for the Care and Use of Ani-
mals for Scientific Purpose (7th Edition, 2004) and the criteria set by The National Centre for the Replacement, 
Refinement and Reduction of Animals in Research (London, UK). All mice were kept under 12 h day/night light 
cycle with the temperature in the animal facility maintained at 23 ± 2 °C and the relative humidity of 55 ± 2%. 
The mice were maintained on normal laboratory chow and given water ad libitum. All procedures were per-
formed under sterile conditions with surgical magnification. Mice were humanely euthanized at the end of the 
study using  CO2 asphyxiation. On completion of an experiment, blood was collected by cardiac puncture and 
the aorta was harvested from the aortic arch to the femoral bifurcation, perfused with phosphate buffered saline 
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(PBS) and processed for subsequent ex vivo morphometry measurements. Approximately 1 mm aortic segments 
immediately below  (CaPO4 model) or above (AngII model) the renal arteries were then harvested. For consist-
ency, the segment close to renal branches was processed for histopathology assessment and the distal segment 
was processed for RNA extraction.
Two different animal models of AAA were used to examine the effect of KAL on AAA:
Calcium phosphate  (CaPO4) mouse model of AAA . This model exhibits aortic dilation associated with inflam-
mation and  apoptosis21,22. This model was used to examine the effect of transgenic overexpression of the human 
KAL gene (KS-Tg) on AAA development. The  CaPO4 model was preferred because the KS-Tg mice were on a 
genetic background of the C57BL/6 strain which is resistant to aneurysm induction by angiotensin II (AngII) 
 infusion13. KAL overexpression was confirmed by genotyping and protein and mRNA expression assessments 
(Supplementary Fig.  S1). Control mice were littermate WT controls, not expressing the KAL transgene. For 
AAA induction, mice were anaesthetised by isoflurane inhalation in conjunction with oxygen during surgery 
(4% isoflurane/O2 inhaled) according to a previously published  protocol21. A midline abdominal incision was 
made and the IRA exposed. A small piece of filter paper (5 mm × 5 mm) pre-soaked in 0.5 mol/l calcium chlo-
ride was affixed to the exterior wall of IRA for 10 min and then removed. A second small piece of filter paper of 
similar size pre-soaked in PBS was then affixed to the same part of the exterior wall of IRA for 5 min and then 
removed. After closing the abdominal wound with sutures, the mouse was allowed to recover under an infrared 
heating lamp until it regained normal physical activity.
Ang II mouse model of AAA . Aneurysms in this model have marked upregulation of inflammatory markers 
similar to human AAA 23,24. Administration of recombinant KAL (rhKAL) is a feasible means to upregulate 
KAL in vivo. In a preliminary study injection of 21.6 µg/kg of rhKAL i.p. led to a measurable level of circulat-
ing KAL after one hour (plasma KAL approximately 1.4 ng/ml). This dose of rhKAL was therefore chosen for 
further investigation. AngII was infusion subcutaneously into apolipoprotein E deficient (ApoE−/−) mice at a rate 
of 1.0 µg/kg/min over 28 days as previously  described11. Osmotic micro-pumps (ALZET Model 1004, Durect 
Corporation, USA) were inserted into the subcutaneous space left of the dorsal midline under anaesthesia (4% 
isoflurane/O2 inhaled) to administer AngII. Male ApoE−/− mice (n = 40) were randomly allocated to receive 
recombinant KAL (rhKAL, R&D Systems, 1669-PI, 21.6 µg/kg/d i.p.) or saline vehicle control (VC) during the 
4 week AngII-infusion.
Mice in both experiments were monitored for 28 days. Systolic blood pressure was measured by tail cuffs 
using the CODA machine (Kent Scientific Corporation) at baseline, 14 and 28 days, as reported  previously11.
Assessment of AAA severity. Maximum aortic diameter was measured in vivo using transabdominal 
ultrasonography during the experiments and by ex vivo morphometry assessment at completion of the study.
Ultrasound measurements of the IRA or SRA were obtained at baseline and at days 14 and 28. Scans were 
performed on anesthetised mice (i.p. 40 mg/kg ketamine and 4 mg/kg xylazine) using a MyLabTM 70 VETXV 
machine (Esaote, Italy) with a 40 mm linear transducer at an operating frequency of 10 MHz (LA435; Esaote, 
Italy) to provide an external sagittal image of the aortic segment assessed. Maximum IRA or SRA diameter was 
measured at peak systole in the anterior to posterior plane from the outer-to-outer aortic wall, using the caliper 
measurement feature as previously reported and as has been shown to be highly  reproducibility11.
Ex vivo morphometry measurements were performed on aortas harvested from mice that completed the full 
28 day experiments. Immediately following euthanasia, the aortas were perfused with PBS under constant physi-
ological pressure, harvested, placed on a graduated template and digitally photographed (Coolpix 4500, Nikon). 
Maximum external diameters of the aortic arch, thoracic aorta, IRA and SRA were determined from the images 
using computer-aided analysis (Adobe Photoshop CS5 Extended, version 12, Adobe Systems Incorporated). 
These measurements have been shown to be highly  reproducible11.
The left and right carotid arteries and aortic arch were cut opened longitudinally and secured with pins on a 
wax-coated petri-dish and photographed (Coolpix 4500, Nikon). The area of the ascending aorta was quantified 
by measurement of the intimal area of the region from the aortic origin to 3 mm proximal to the subclavian artery 
(Adobe Photoshop CS5 Extended, version 12, Adobe Systems Incorporated) following a previously published 
 protocol25.
Quantification of atherosclerotic lesion area. The severity of atherosclerosis was quantified through 
examination of the intimal surface of the ascending aorta by en face Sudan IV staining as previously  described26. 
The aortic tissue samples were transferred from PBS to a 70% ethanol solution and stained with 0.1% Sudan IV 
dissolved in equal parts of acetone and 70% ethanol for 10 min. Background staining was washed off by 10 min 
incubation in 70% ethanol. Samples were rehydrated by brief placement in  H2O and digitally photographed in 
order to identify areas of staining (Coolpix 4500, Nikon). Sudan IV stained areas were quantified using Adobe 
Photoshop software (version CS5). The atherosclerotic lesion area was estimated as a percentage of the total 
luminal surface area stained, as previously  described26.
Assessment of plasma cytokine levels. Platelet poor plasma samples were examined by a multiple ana-
lyte mouse inflammation cytometric bead array (CBA, BD Biosciences) to quantitatively concentrations of inter-
leukin (IL)-6, IL-10, monocyte chemoattractant protein-1 (MCP-1), interferon-gamma (IFN)-γ, tumor necrosis 
factor (TNF)-α and IL-12p70 according to the manufacturer’s instructions. Flow cytometry was performed on a 
CyAn ADP flow cytometer (Beckman Coulter) and results were analysed with FCAP Array software (v3.0, BD 
Biosciences), following previously published  protocols21. This method has a coefficient of variation of 6–9%21.
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Histopathological assessments. IRA or SRA segments (n = 6–8/group) stored in O.C.T. compound, 
from each experimental group were selected using a random number generator. 6 µm thick sections were seri-
ally cut from the aorta immediately below  (CaPO4 model) or above (AngII model) the renal arteries. Adjacent 
sections. (3–4 sections/sample) were stained with Hematoxylin and eosin (H&E, ProSciTech) and elastin van 
Gieson (EVG; Polysciences, Inc). The sections were photographed using a Nikon Eclipse 50i microscope fitted 
with a CCD Camera (DSFi1) and digital images captured (NIS Elements vF2.30). Elastin filament fragmentation 
was assessed under 400× magnifications from 2 to 3 aortic sections from each mouse and was graded as follows: 
1—no elastin breaks, 2—mild breaks; 3—moderate to severe breaks; and 4—severe elastin filament fragmenta-
tion. These assessments can be performed with good inter-observer  reproducibility21.
For collagen staining, serial cryostat sections (6 µm thickness) were fixed in 80% methanol at – 20 °C before 
rehydration in distilled water. Sections were then placed in Weigerts hematoxylin (ProSciTech) followed by 
rinsing in distilled water until the water was clear. Sections were then placed in Picro Sirius Red solution (Pro-
SciTech) for 60 min followed by quickly removing excess Picro Sirus Red in 70% ethanol. Sections were then 
dehydrated in serial ethanol solutions and two xylene solutions. Images of stained sections were taken under a 
light microscope using reflective transmitted light and a circular polarising filter (Zeiss Axiovision). Sections 
were photographed with identical exposure setting for each section. Images were analysed in Adobe Photoshop 
CS6 software using the area measurement tool to calculate collagen content percentage in the total section area. 
The percentage of birefringence was determined for 4–5 fields for at least three sections per mouse and the mean 
value was calculated for each region as described  previously11. These assessments are highly  reproducible11.
TUNEL staining. In situ terminal deoxynucleotidyl transferase mediated dUTP nick-end labelling 
(TUNEL) was performed using an in situ apoptosis kit (VasoTACS, Trevigen) to localize cells undergoing nuclear 
DNA fragmentation. Cryostat sections (6 µm) from the IRA and SRA were processed for the TUNEL assay as 
described  previously26 and both positive and negative control slides were included (n = 6/group). The presence 
of apoptotic cells was identified as dark nuclear staining with the distinctive morphological appearance associ-
ated with cell shrinkage and chromatin condensation (apoptotic cells) or cytoplasmic fragments with or without 
condensed chromatin (apoptotic bodies). The images were captured at 400× magnification and percentage of 
positive staining area was calculated by dividing the positive staining area by the total area of the region selected. 
For each region of interest, a spot check was performed by visually counting the cells and avoiding necrotic areas. 
All histological evaluations were done in a blinded fashion in at least 3–4 sections per sample. These assessments 
can be performed with good reproducibility (Intra-assay coefficient of variation = 3%)26.
In situ imaging of superoxide. Oxidative stress was estimated in unfixed frozen tissue sections from 
O.C.T. embedded IRA and SRA segments stored at –  80  °C using dihydroethidium staining (DHE, Sigma-
Aldrich) according to a previously published  protocol27. Briefly, cryosections (6 µm, n = 6/group) were brought 
to room temperature for 5 min. Slides were covered with Hanks’ Balanced Salt solution (HBSS, Sigma-Aldrich) 
for 5 min, then DHE solution in HBSS was added to sections for 20 min at room temperature in a dark, humidi-
fied chamber. Slides were transferred to a 37 °C incubator for 30 min. Slides were washed three times with HBSS, 
washed with PBS and mounted on coverslip using antifade mounting medium (VECTASHIELD, Vector Labs). 
Fluorescent images were captured with a microscope and scored for red fluorescence intensity by an observer 
blinded to the experimental group (580-nm filter, Zeiss Axiovision). Quantitative measurements of the DHE 
fluorescence intensity were performed using the inbuilt software (Zeiss Axiovision). The average pixel intensities 
were calculated and reported as DHE intensity Arbitrary Units (A.U.).
SIRT1 deacetylase activity assay. Nuclear proteins were extracted from randomly selected IRA and 
SRA segments using a nuclear extraction kit (Abcam) according to the manufacturer’s instructions. The SIRT1 
activity was assayed using a SIRT1 activity assay kit (Abcam) according to the manufacturer’s instructions. The 
kit measures the activity of SIRT1 based on fluorescence intensity using a microplate reader with an excitation 
wavelength of 350 nm and an emission wavelength of 460 nm (BMG Labtech). The measured fluorescence is 
directly proportional to the deacetylation activity of the enzyme within the sample and results were presented as 
relative fluorescence units (RFU)/μg protein.
Cell culture studies. Commercially available healthy human aortic VSMCs (CC-2571, Lonza) were seri-
ally passaged using trypsin/EDTA (Sigma Aldrich) and used for experiments between passages three and six. 
For some VSMC experiments, cells were incubated with conditioned medium obtained from AAA intra-lumi-
nal thrombus (ILT) explant cultures. The preparation of ILT-conditioned media was as previously  published11. 
Briefly, ILT tissues were rinsed and sliced finely in sterile PBS (pH 7.4) and incubated in DMEM [supplemented 
with penicillin, streptomycin, glutamine, 5% (vol/vol) FBS and 2 µg/ml Fungizone] at 37 °C in a humidified 5% 
 CO2 atmosphere. The culture media was refreshed after 1 h and the explants were cultured for a further 20.5 h to 
provide ILT-conditioned media. The thrombus conditioned media was decanted and centrifuged at 5000×g for 
10 min to pellet large debris and the supernatants containing secreted thrombus proteins were snap frozen and 
stored at – 80 °C. Cells (1 ×  106 cells/ml) were plated out in 12 well culture plates and incubated with 5% DMEM 
(Gibco). After settling overnight, cultures were replenished with fresh media that contained ILT-conditioned 
media for 24 h and media removed and replenished with fresh media plus 10 nM rhKAL (1669-PI, R&D Sys-
tems) or varying doses of fenofibrate for an additional 24 h. The control group received a fresh media change at 
the same time. For AAA-Body and AAA-Neck VSMCs, all experiments were conducted using cells at passage 
three (Supplementary Table S3). At the end of experiment period, supernatant was removed and cells harvested 
for both protein and RNA isolation. For protein extraction, cells were harvested in RIPA buffer (Cell Signalling 
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Technology) containing protease inhibitors (Roche) and phosphatase inhibitors (Pho-STOP, Roche). Protein 
concentration was determined by using the BioRad protein assay (Bio-Rad Laboratories) and SERPINA4 con-
centration levels were assessed (#CSB-EL021060HU, CUSABIO) according to the manufacturer’s recommen-
dations. Cells were collected into RNAlater (Ambion) for RNA isolation using RNeasy Mini kit following the 
manufacturer’s protocol (Qiagen). All experiments were performed in triplicate.
Assessment of apoptosis in vitro. Caspase-3 activity was measured in homogenates of VSMCs using the 
Caspase-Glo 3/7 assay kit (Promega) according to the manufacturer’s instructions. Luminescence activity was 
measured within 30–60 min, in six separate experiments using the Polar Star Omega (BMG Labtech).
Assessment of oxidative stress in vitro. VSMCs were plated on opaque, multiwell plates and incubated 
with ILT-conditioned media and rhKAL as explained in the previous sections. At the end of the experiment 
period, the ROS-Glo™  H2O2 substrate (Promega) was incubated directly with cells in culture media to generate a 
luciferin precursor. Addition of ROS-Glo™ Detection Solution converted the precursor to luciferin and produced 
a light signal that is proportional to the level of  H2O2 present in the sample. Luminescence activity was measured 
within 30 min, in six separate experiments using the Polar Star Omega (BMG Labtech).
mRNA analysis by quantitative real-time PCR. Total RNA was isolated from IRA or SRA segments, 
human AAA tissues and VSMCs. At the time of harvest a segment of IRA or SRA was stored in RNA Later 
(Qiagen). Aortas were selected using a random number generator for the gene expression analysis (n = 8/group) 
and initial tissue digestion was processed using a bullet blender with stainless beads to maximise the yield. For 
RNA isolation from cell culture experiments, cells were harvested after experiments in Trizol (Qiagen). Total 
RNA was isolated using an RNeasy Mini kit (Qiagen) according to manufacturer’s instructions and quantified 
spectrophotometrically using the Nanodrop 2000. RNA samples were subjected to quantitative real time PCR 
(QRT-RCR) analysis of genes of interest using the QuantiTect SYBR Green one-step RT-PCR assay (Qiagen). 
QRT-PCR was performed to evaluate gene expressions using primers for human SERPINA4, SIRT1, Matrix 
metalloproteinase-9 (MMP-9), MMP-2, vascular endothelial growth factor (VEGF) and Glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) and mouse Mmp-9, Mmp-2, Vegf, Osteoprotegerin (Opg), Osteopontin (Opn) 
and Gapdh (Qiagen). Primers are listed in Supplementary Table S4. The relative expression of these genes was 
calculated by using the concentration-Ct-standard curve method and normalized using the average expression 
of glyceraldehyde-3-phosphate dehydrogenase (human: GAPDH, QT00079247; mouse: Gapdh; QT01658692) 
for each sample using the Rotor-Gene Q operating software (version 2.0.24).
Statistical analysis. For human studies, quantitative data were not normally distributed and therefore 
were presented as median and inter-quartile range (IQR) and compared between groups using appropriate non-
parametric tests including Mann Whitney U and Kruskal–Wallis tests. Nominal data were presented as number 
and percentages and compared by Chi-squared test. Men were divided into quartiles based on serum KAL. The 
association of serum KAL with AAA diagnosis was assessed using multiple logistic regression analysis adjust-
ing for age, CHD, hypertension, diabetes, smoking, stroke, waist-to-hip ratio (WHR), serum creatinine, HDL, 
LDL and aspirin prescription. In men with repeat ultrasound imaging, change in AAA diameter was calculated 
by averaging the change between successive ultrasound scans and adjusting for the observation time as previ-
ously  described28. Since average weighted yearly change in AAA diameter was associated with the initial AAA 
 diameter29, the association between serum KAL and average AAA growth per year was also expressed as a 
percentage of the initial AAA diameter. Furthermore, the association of serum KAL quartile with AAA growth 
greater than median was analysed by logistic regression, adjusting for other risk factors, including initial AAA 
diameter, diabetes and serum CRP. The relationship between serum KAL and AAA growth was also assessed 
using linear regression adjusting for the same risk factors.
For mouse studies, the normality of the data was tested using the D’Agostino and Pearson omnibus normality 
test. Results are expressed as median and interquartile range (IQR) for non-normally distributed data and as 
mean ± standard error of mean (S.E.M) for normally distributed data. Normally distributed data were compared 
using t test or ANOVA. Comparison for non-normally distributed data were made using Mann–Whitney U-test 
or Kruskal–Wallis test, where appropriate. The change of aorta diameter over time measured with ultrasound 
and blood pressure measurements during the experimental period were assessed using repeated measures 2-way 
ANOVA. Kaplan–Meier survival curves were analysed using log-rank (Mantel-Cox) test. Data was analysed 
using SPSS software (version 22) or by GraphPad Prism (version 7). In all cases, P values <0.05 were considered 
significant.
Results
Serum KAL was negatively associated with AAA diagnosis. The risk factors of the 956 men 
included in relation to whether they had an AAA diagnosed or not are shown in Supplementary Table S1. Serum 
KAL concentrations were significantly lower in men diagnosed with an AAA. Serum KAL quartiles were incre-
mentally associated with reducing risk of having an AAA after adjusting for other risk factors (Table 1). Men 
with serum KAL concentrations in the second, third and fourth quartiles had a 0.50 (95% confidence intervals, 
CI 0.33–0.75), 0.47 (95% CI 0.31–0.71) and 0.31 (95% CI 0.20–0.48) odds ratio of having an AAA diagnosed, 
respectively, by comparison to men with serum KAL concentrations in the first quartile. An increase of 6 ng/
ml of serum KAL concentration (approximately standard deviation) was associated with a 0.73 odds reduction 
(95% CI 0.62–0.86) of having an AAA diagnosed after adjusting for other risk factors (Table 1).
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Serum KAL was negatively associated with AAA growth. Men with AAA (n = 272) measuring a 
median (IQR) initial IRA diameter of 32.9 mm (31.0–36.1) were followed for a median (IQR) of 5.5 years (5.0–
6.0) with a median of 7 (6–7) ultrasound scans. Median (IQR) annual increase in maximum AAA diameter 
(AAA growth) was 1.2 mm/year (0.5–1.9). AAA growth was negatively correlated with serum KAL concentra-
tion (Spearman’s rho − 0.173, p = 0.004; Supplementary Fig. S2). Men with serum KAL in the lowest quartile had 
significantly greater rate of AAA growth whether assessed in mm increase/year or percentage of initial diameter 
increase (Supplementary Table S2). Serum KAL was negatively associated with AAA growth after adjusting for 
initial AAA diameter, diabetes and serum high sensitive C-reactive protein (hs-CRP) using linear regression 
(Beta − 0.118, p = 0.036) and logistic regression (Table 2).
Transgenic overexpression of human KAL in mice attenuated  CaPO4-induced aortic expan-
sion. AAA was induced by application of  CaPO4 to the IRA of the KS-Tg and WT mice and expansion of the 
IRA was assessed by ultrasound and morphometry. Ultrasound imaging suggested that prior to  CaPO4 applica-
tion the maximum diameter of the IRA was similar in KS-Tg and WT mice. Following application of  CaPO4 the 
external diameter of the IRA increased significantly more in WT than in KS-Tg mice over 28 days (p = 0.047; 
Fig. 1A, Supplementary Fig. S3) when assessed by ultrasound.
At the end of the experiments, aortas were harvested and examined ex vivo. Visible IRA dilation was noted 
in 6 out of 13 WT mice and in one of the 12 KS-Tg mice (Supplementary Fig. S4). Morphometric assessment 
showed that the WT mice had a mean (± SEM) maximum exterior IRA diameter of 1.29 ± 0.15 mm compared to 
0.79 ± 0.03 mm for KS-Tg mice (p = 0.010; Fig. 1B). En face measurement of intimal surface area of the ascending 
aorta was used as an index to determine ascending aortic dilation. No difference between genotypes was observed 
(p = 0.586; Fig. 2A; Supplementary Fig S5.A).
Administration of recombinant human KAL inhibited AngII-induced AAA in  ApoE−/− 
mice. AngII-infusion induced fatal aortic rupture in 13 of the 40 mice (33%) within 14 days. Administration 
of rhKAL did not influence survival free from aortic rupture (Supplementary Fig. S6). Ultrasound imaging dem-
Table 1.  The independent association of serum KAL quartiles with AAA diagnosis assessed using multiple 
logistic regression in samples from 956 men. Both models were adjusted for hypertension, diabetes, ever 
smoking, coronary heart disease, past history of stroke, waist to hip ratio, serum creatinine, serum low density 
lipoprotein, serum high density lipoprotein and C-reactive protein. AAA, Abdominal aortic aneurysm; 
CI, confidence interval; KAL, kallistatin. *Approximate standard deviation of KAL. a Men with serum KAL 
concentrations in the top, third and second quartiles were compared with subjects who had serum KAL in the 
lowest quartile.
Characteristic Odds ratio 95% CI P value
Model 1
Serum KAL per 6 ng/ml* 0.73 0.62–0.86 < 0.001
Model 2
Serum KAL in ng/mla
 < 13.15 1 Reference
 13.15–16.29 0.50 0.33–0.75 0.001
 16.30–20.30 0.47 0.31–0.71 < 0.001
 > 20.30 0.31 0.20–0.48 < 0.001
Table 2.  Independent risk factors for AAA growth greater than median in 272 men. For nominal variables, 
the comparisons are to subjects without the risk factor. AAA, Abdominal aortic aneurysm; CI, confidence 
interval; hs-CRP, high sensitivity C-reactive protein; KAL, kallistatin. *Men with serum KAL concentrations 
in the top, third and second quartiles were compared with subjects who had serum KAL in the lowest quartile. 
a Approximately median value.
Characteristic Odds ratio 95% CI P value
Serum KAL in ng/ml*
 < 11.96 1 Reference
 11.96–14.85 0.46 0.22–0.96 0.038
 14.86–18.00 0.36 0.17–0.76 0.007
 > 18.00 0.49 0.24–1.04 0.062
Initial AAA diameter > 32.90  mma 2.99 1.78–5.01  < 0.001
Diabetes mellitus 0.27 0.11–0.67 0.005
Serum hs-CRP > 2.46 mg/mla 0.81 0.48–1.37 0.444
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onstrated that in surviving mice AngII-induced increase in SRA diameter was significantly inhibited by rhKAL 
administration (p = 0.030; Fig. 1C).
Ex vivo external diameter measurement of harvested aortas from all surviving mice demonstrated that mice 
receiving rhKAL had significantly smaller maximum external SRA diameter. The mean (SEM) external SRA 
diameter of the control group (2.48 ± 0.18 mm) was significantly greater than that of the mice receiving rhKAL 
(1.77 ± 0.20 mm, p = 0.009; Fig. 1D; Supplementary Fig. S7). A smaller maximum external diameter was also 
observed within the aortic arch (p < 0.001), thoracic aorta (p < 0.001) and IRA (p = 0.017) in the AngII-infused 
ApoE−/− mice receiving rhKAL compared to the control group (Fig. 1D). Subsequent assessment of en face 
measurement of intimal surface area of the ascending aorta showed a corresponding significantly smaller mean 
intimal ascending aortic area in AngII-infused ApoE−/− mice receiving rhKAL compared to the control group 
(p = 0.003; Fig. 2A; Supplementary Fig S5.B).
KAL limited atherosclerosis in the AngII-infused not the CaPO4 model. The systolic blood pres-
sure of KS-Tg and WT mice was not significantly different (Supplementary Fig. S8.A). Body weight of KS-Tg 
mice was greater than WT mice throughout the experiment (Supplementary Fig. S9.A). rhKAL administration 
did not significantly affect systolic blood pressure or body weight (Supplementary Fig. S8.B and Fig. S9.B). No 
difference was observed between the WT and the KS-Tg genotypes in Sudan IV enface staining (Fig. 2B). The 
Figure 1.  The effect of human KAL upregulation in AAA mouse models. (A, B). Effect of transgenic 
overexpression of KAL on  CaPO4-induced aortic dilatation. (A) Shown are maximum external IRA diameter of 
WT (n = 13) and Kal-Tg (n = 12) mice both subjected to peri-aortic  CaPO4 application assessed by ultrasound 
and followed up for 28 days. Quantification graph showing mean and standard error of mean (SEM) analysed 
by Repeated measures two-way ANOVA and statistical significance shown as *P < 0.05. (B) Regional maximum 
diameters of WT and KS-Tg mice receiving peri-aortic application of  CaPO4 determined by direct ex vivo 
morphometric measurements at the end of the 28 days study period. Ex vivo measurement of mean maximum 
aortic diameter showed that KS-Tg mice receiving  CaPO4 resulted in significantly smaller IRA diameters when 
compared to the WT control mice. Quantification graph showing median and interquartile ranges (whiskers) 
analysed by Mann Whitney U test and statistical significance shown as **P = 0.01. (C, D) Effect of rhKAL on 
AngII-induced aortic dilatation in ApoE−/− mice. (C) Shown are maximum external SRA diameter of ApoE−/− 
administered with VC (n = 20) or rhKAL (n = 20), both subjected to 28 days of AngII-infusion. *P < 0.05. (D) 
Regional maximum diameters of ApoE−−- mice administered with either VC or rhKAL determined by direct 
ex vivo morphometric measurements at the end of 28 days of AngII infusion. Ex vivo measurement of aortic 
arch, thoracic, SRA and IRA regions showed that mice receiving rhKAL had a significantly smaller maximum 
diameter when compared to controls. Quantification graph showing median and interquartile ranges (whiskers) 
and statistical significance shown as *P < 0.05, **P < 0.01, ***P < 0.001. IRA, infrarenal aortic diameter; KS-Tg, 
kallistatin transgenic; rhKAL, recombinant human KAL; SRA, suprarenal aortic; Trx, thoracic; VC, vehicle 
control; WT, wild type; AngII, angiotensin II; ApoE−/−, apolipoprotein E deficient;  CaPO4, calcium phosphate.
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rhKAL administered group had a significantly lower staining area compared to the VC group, with a median 
staining area of 20.90% (1QR 15.05–30.92) versus 12.78% (IQR 10.53–20.13, p = 0.016; Fig. 2B).
Transgenic overexpression of KAL reduced plasma concentrations of inflammatory cytokines 
in the  CaPO4 AAA model. Out of the six cytokines assessed, significantly lower concentrations of TNF-α, 
INF-γ, IL-10 and IL-12 where found in the plasma of KS-Tg compared to the WT mice at the end of the experi-
ment (Table 3). In contrast, the administration of rhKAL in the AngII-ApoE−/− model did not significantly affect 
plasma concentrations of these cytokines (Table 3).
KAL reduced aortic wall remodelling in the mouse models. The degree of elastin filament disrup-
tion was significantly greater within the IRA or SRA from the WT compared with the KS-Tg or mice receiving 
rhKal compared to controls (Fig. 2C, Supplementary Fig. S10). The collagen content was assessed by polarisation 
microscopy revealing significantly higher collagen content in the IRA of KS-Tg (median staining area 20.90%, 
IQR 12.04–29.86) compared to WT mice (median staining area 12.24%, IQR 8.78–14.29; p = 0.040; Fig. 2D, Sup-
plementary Fig. S10). Similarly, a higher collagen birefringence was noted in the SRA of mice receiving rhKAL 
(median staining area 33.52%, IQR 25.80–44.10) compared to the control group (median staining area 16.82%, 
IQR 14.64–24.36; p = 0.009; Fig. 2D).
Figure 2.  The effect of KAL in the aorta of  CaPO4 induced and AngII-induced AAA mouse models. (A) 
Ex vivo morphometry measurement of ascending aortic aneurysm measured using an en face method. (B) 
Percent atherosclerosis lesion area of thoracic aorta measured by en face Sudan IV staining method. (C) 
Quantification graph showing elastin filament degradation (n = 6 aorta/group). Aortic wall elastin filament 
degradation was graded based on the degree of breaks in elastin filaments (graded on a scale of 1–4) as 
described in the materials and methods. (D) Quantification of polarisation images for collagen content 
expressed as a percentage (%) of the total IRA and SRA section areas in the  CaPO4 and AngII models, 
respectively (n = 6 aorta/group). Data shown as median and interquartile range and analysed by Mann–Whitney 
U test. Statistical significance shown as *P < 0.05, **P < 0.01. AngII, angiotensin II; n.s., not significant; rhKAL, 
recombinant human Kallistatin; Kal-Tg, kallistatin transgenic; SRA, suprarenal aortic diameter; IRA, infrarenal 
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KAL attenuated oxidative stress and VSMC apoptosis. Elevated oxidative stress was identified by the 
number of DHE-positive cells in the aortic wall.  CaPO4 administration and AngII infusion led to marked DHE 
staining which was reduced by transgenic KAL [WT median DHE intensity, 15.04AU (IQR 12.85–18.82) versus 
KS-Tg median DHE intensity 7.55AU (IQR 6.77–11.49), p = 0.002; Supplementary Fig. S11] and administration 
of rhKAL [VC 25.58AU (IQR 21.62–28.77) versus rhKAL 14.97AU (IQR 12.36–17.89), p = 0.002; Fig. 3A].
Median (IQR) of TUNEL staining area was significantly higher in sections of the IRA of WT mice compared 
to KS-Tg mice (21.50%, IQR 19.16–23.05 vs. 11.46%, 8.61–13.41, p = 0.002; Fig. 3B; Supplementary Fig. S11). 
Similarly, median (IQR) TUNEL staining area was higher in the SRA sections from VC group (30.98%, IQR 
27.87–34.30) compared to the rhKAL administered group (12.84%, 9.61–19.28, p = 0.007; Fig. 3B). The TUNEL 
positive apoptotic cells were mostly located in the medial region of IRA and SRA suggesting these were VSMCs. 
Hence, in vitro VSMC studies were conducted. Incubating VSMCs with human AAA-thrombus derived con-
ditioned medium for 24 h promoted apoptosis in these cells as assessed by mean relative luminescence units 
(RLU, p = 0.001; Fig. 3C). Addition of 10 nM rhKAL to conditioned media-exposed VSMCs for 24 h resulted 
in a significant reduction in apoptosis (p = 0.009; Fig. 3C). In addition, exposure of VSMCs to AAA-thrombus 
derived conditioned medium for 24 h resulted in marked upregulation of ROS activity (p < 0.001; Fig. 3D), an 
effect that was significantly reduced in the presence of rhKAL (10 nM RLU, p = 0.001; Fig. 3D).
KAL attenuated expression of ECM remodelling genes. QRT-PCR analysis was performed to assess 
the relative expression of Mmp-9, Mmp-2, Opg, Opn and Vegf in the IRA and SRA samples from both mouse 
studies. The relative expressions of Mmp-9, Mmp-2 and Opn were significantly downregulated in the IRA sam-
ples of KS-Tg compared to WT mice (Table 4), however, remained comparable in AngII-infused ApoE−/− mice 
receiving rhKAL or vehicle control (Table 4).
VSMC dysfunction, in response to cytokines released from AAA-thrombus or to AngII, is thought to play an 
important role in dysregulated ECM remodelling associated with AAA 30,31. Significant upregulation in MMP-
9 and VEGF expression in VSMCs cultured in the presence of AngII (2 nM) or with AAA-thrombus derived 
conditioned medium over 24 h was attenuated in the presence of rhKAL (10 nM; Fig. 4A–D).
KAL upregulates SIRT1. KAL has been shown previously to reduce ROS production through the SIRT1 
 pathway32. Nuclear SIRT1 activity was assessed in IRA and SRA tissue from the mouse models. Nuclear protein 
extract obtained from KS-Tg mice and ApoE−/− mice receiving rhKAL showed increased SIRT1 activity com-
pared to controls (Fig. 5A). Expression of the SIRT1 gene was assessed in AAA body and neck samples from 
patients and found to be similar (Fig.  5B). Subsequently, VSMCs isolated from paired AAA body and neck 
samples were assessed and found that AAA-VSMCs isolated from aneurysmal body had comparatively lower 
expression levels of SIRT1 compared to VSMCs from relatively disease-free neck (Fig. 5C).
Fenofibrate upregulates KAL in VSMCs. A previous study from our group found that fenofibrate effec-
tively reduced AAA in the AngII  model26. Fenofibrate has also been shown to ameliorate anti-oxidative effect 
by regulating the expression of oxidant and anti-oxidant  enzymes33. Since SIRT1 expression was downregulated 
in AAA-derived VSMCs and it was previously reported that fenofibrate increases cardiac expression of  SIRT134, 
the effect of fenofibrate was examined on VSMCs. VSMCs were incubated with increasing concentrations of 
fenofibrate and the KAL protein concentration and SERPINA4 mRNA in cell culture supernatant and VSMCs 
were measured. Fenofibrate (0–100 µM) dose-dependently increased supernatant concentrations of KAL pro-
tein (Fig. 5D) and stimulated SERPINA4 expression compared to controls at the maximum dose of 100 µM 
(Fig.  5E). Subsequently, AAA-VSMCs were incubated with fenofibrate which significantly upregulated SER-
PINA4 expression (Fig. 5F).
Table 3.  Concentrations of cytokines (pg/ml) in the plasma of AAA animal models at the end of the 28 days 
experiment period. Data presented as median (interquartile range, IQR) and statistical analysis performed 
using Mann Whitney U test. P value of < 0.05 was considered significant. AAA, Abdominal aortic aneurysm; 
AngII, angiotensin II;  CaPO4, calcium phosphate; IFN-γ, Interferon gamma; IL, Interleukin; KS-Tg, kallistatin 
transgenic; MCP-1, Monocyte Chemoattractant Protein-1; ND, not detected; rhKAL, recombinant human 
Kallistatin; TNF, Tumour Necrosis Factor; VC, vehicle control; WT, wild type.
Samples
CaPO4 AAA model AngII AAA model
WT (n = 8) KS-Tg (n = 8) P value VC (n = 8) rhKAL (n = 8) P value
TNFα 16.54 (6.67–90.01) 4.13 (2.11–6.57) 0.005 3.97 (3.63–7.68) 5.13 (4.05–5.97) 0.688
IL-12p70 75.25 (10.62–285.00) 8.00 (0–13.82) 0.004 7.86 (1.98–18.24) 9.36 (6.22–20.02) 0.548
IFN-γ 3.25 (0.96–12.64) 0.73 (0.32–1.08) 0.007 0.78 (0.47–1.31) 0.73 (0.62–1.17) 0.362
IL-10 41.33 (0–207.20) ND 0.015 ND ND
MCP-1 59.70 (22.39–129.80) 20.85 (0–76.17) 0.207 35.71 (34.18–221.20) 31.65 (5.34–255.80) 0.571
IL-6 7.51 (3.62–47.81) 6.22 (2.23–13.30) 0.481 5.42 (3.70–8.23) 5.66 (3.12–14.84 )  > 0.999
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Discussion
The main findings of this study were that serum KAL was negatively associated with AAA diagnosis and growth, 
and that within mouse models upregulating KAL reduced the size of AAAs. The findings suggest that KAL plays 
a protective role against AAA. A previous proteomic study identified KAL as one of the five proteins found to 
be differentially up-regulated in AAA  patients35. This previous study included only a small number of hospital 
recruited patients under investigation for coronary artery disease (17 AAA patients and 17 controls). A more 
recent study also reported upregulation of KAL in AAA human samples when assessed by Western blotting but 
reported downregulation of KAL when analysed by real time PCR (36 AAA patients and 12 controls)36. Neither 
study analysed aortic cells. In contrast, in the current study we investigated VSMCs isolated from AAA patients 
and blood from approximately 1000 men aged over 65 years recruited from the community and screened for 
AAA. We found a negative association between serum KAL and AAA diagnosis and growth. The AAAs identi-
fied in this cohort were mostly small and therefore the findings are likely representative of the association of 
KAL with early stage AAA.
Figure 3.  The effect of KAL on oxidative stress and apoptosis in  CaPO4 induced and AngII-induced AAA 
mouse models and in vitro. (A) Quantitative data showing mean fluorescence was quantified and expressed as 
DHE staining intensity (%). Data expressed as median and interquartile range with maximum and minimum 
data points (whiskers) for positive staining area relative to total specimen area (%); *P < 0.05, **P < 0.01 by 
Mann–Whitney U test (n = 6 aorta/group). (B) Quantitative data showing TUNEL staining, shown is data 
expressed as median and interquartile range with maximum and minimum data points for positive staining 
area relative to total specimen area (%); **P < 0.01 by Mann–Whitney U test (n = 6 aorta/group). (C, D) VSMCs 
were plated at 1 ×  106 cells/ml in 500 µl DMEM + 5% FBS and allowed to adhere overnight. Exposure of VSMCs 
to AAA thrombus-derived conditioned medium for 24 h (n = 6/group) promoted both apoptosis (C) and 
upregulation of ROS activity (D) in these cells as assessed by mean relative luminescence unit (RLU). Addition 
of 10 nM rhKAL to the conditioned media resulted in significant reduction in both apoptosis and ROS activity 
(C,D). All experiments were performed in triplicate (n = 6/group). Analysis performed by Kruskal Wallis test 
and post hoc analysis and statistical significance shown as *P < 0.05; **P < 0.01; ***P < 0.001. AngII, angiotensin 
II; DHE, dihydroethidium; Kal-Tg, kallistatin transgenic; rhKAL, recombinant human Kallistatin; SRA, 
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Inflammation is thought to play an important role in human AAA pathogenesis and several studies suggest 
that KAL limits  inflammation10,37. Transgenic overexpression of KAL in mice resulted in significant reduction in 
the plasma levels of a number of cytokines including TNF-α, IFN-γ, IL-10 and IL-12 after AAA induction. TNF-α 
is considered a key stimulant of pro-inflammatory responses by promoting cytokine release, oxidative stress and 
 angiogenesis10. IFN-γ is a cytokine that stimulates T cells and macrophages based immune  responses38. IFN-γ 
concentrations have been reported to be increased in human AAA 39. These effects may have been important 
in the relative AAA resistance of the KS-Tg mice but was not found in the mice receiving rhKAL and therefore 
other mechanisms were examined.
Elastin fragmentation, collagen destruction and VSMC apoptosis are important features of human AAA 
and have been implicated in AAA development within the  CaPO4 and AngII  models21. The histopathological 
assessment in the current study suggested that transgenic overexpression of KAL and administration of rhKAL 
limited elastin degradation and attenuated fibrosis. These findings are in line with a number of previous studies 
that suggested that KAL upregulation limits ECM  remodelling9,40–43. Matrix regulating proteins such as MMPs, 
OPN, OPG and VEGF have been previously implicated in experimental and human AAA 44–47. In the KS-Tg mice, 
but not mice receiving rhKAL, Mmp-9, Mmp-2 and Opn expressions were downregulated. The disparate effects 
of the two methods of upregulating KAL is likely explained by the less powerful increase in KAL achieved by 
intermittent i.p. injection as compared to transgenic upregulation. Also the findings were likely contributed to 
by the different models used. The AngII infused AAA model has greater ECM remodelling and inflammation 
than the  CaPO4 model which may have overwhelmed the effects of rhKAL.
Apoptosis of VSMCs is known to be important in experimental and human AAA 48,49. In the current study, 
KAL upregulation limited DHE and TUNEL staining within the aorta in both AAA models. Furthermore, 
administration of rhKAL inhibited apoptosis of healthy VSMCs in vitro. Incubation of VSMC with rhKAL also 
inhibited ROS generation in these cells stimulated by exposure to human AAA-thrombus conditioned media or 
AngII. Taken together, the findings from the experimental mouse models and in vitro studies suggest that KAL 
inhibited AAA by blocking inflammation, ROS generation and VSMC apoptosis.
SIRT1 expression in VSMC is required to maintain the structural integrity of the aortic wall in response 
to oxidant and inflammatory  stimuli50 and recent studies suggest that VSMC SIRT1 plays a protective role 
in the AngII-infused AAA  model51. SIRT1 has been reported to protect against aortic rupture in response to 
 AngII52,53. VSMC-specific knockout of Sirt1 has been reported to accelerate AngII-induced formation and rup-
ture, whereas VSMC-specific overexpression of Sirt1 suppressed AngII-induced AAA formation and progres-
sion in ApoE−/− mice. The current study suggests that KAL upregulation increased SIRT1 activity, which likely 
contributed to the reduced AAA severity in these mice. SIRT1 expression in tissues obtained from human AAA-
body and AAA-neck was similar. However, when a pure population of VSMCs isolated from the tissues were 
assessed, the SIRT1 expression was shown to be significantly downregulated in AAA-body VSMCs compared to 
the VSMCs from the relatively normal region of the AAA-neck.
Table 4.  Relative gene expressions in the aortas of WT and KS-Tg mice in the  CaPO4 model and mice 
receiving vehicle control or rhKAL in the AngII-infused ApoE−−- mouse model after 28 days. CaPO4 induced 
AAA model was developed in WT and KS-Tg mice and received peri-aortic administration of CaPO4. 
AngII-induced AAA model received daily subcutaneous injection of VC or rhKAL for 28 days. Total RNA 
was isolated from randomly selected aorta tissues stored in RNAlater (n = 8/group) at the end of the study and 
gene expression was assessed by quantitative real time PCR. Data expressed as median (interquartile range, 
IQR). Results are compared by Mann Whitney u test and expressed as relative expression of gene compared to 
glyceraldehyde 3–phosphate dehydrogenase (Gapdh). AAA, Abdominal aortic aneurysm; AngII, angiotensin 
II;  CaPO4, calcium phosphate; WT, wild type; KS-Tg, kallistatin transgenic; rhKAL, recombinant human 
kallistatin; Mmp, matrix metallioproteinase; Vegf, vascular endothelial growth factor, Opg, osteoprotegerin, 
Opn, osteopontin; VC, vehicle control.






























KS-Tg 0.95 (0.38–1.17) rhKAL 0.81 (0.43–2.53)
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Fenofibrate is a peroxisome-proliferator-activated receptor-α agonist, which is used clinically to lower triglyc-
eride levels. Previous mouse model studies suggest that fenofibrate inhibits AAA  development26,54. The Fenofi-
brate in the Management of Abdominal Aortic Aneurysm (FAME)-2 trial showed that 24 weeks of fenofibrate 
therapy did not significantly influence the circulating concentrations of AAA-associated proteins including 
osteopontin and KAL despite reducing serum  triglyceride55. However, the study was underpowered to examine 
the relation between fenofibrate and AAA growth. A further ongoing trial (FAME-1) is examining the effect of 
fenofibrate on the aortic wall. In the current study, fenofibrate upregulated KAL expression in VSMCs in vitro in 
a dose dependent manner, and a similar effect was observed in AAA-VSMCs, which could provide an approach 
by which fenofibrate might act to inhibit AAA progression.
The strengths of this study include the assessment of circulating KAL in a large number of men and the 
further examination of these findings in two rodent AAA models and in vitro studies. Some limitations of this 
study are acknowledged. First, since KAL has pleotropic functions, it is not possible to exclude the possibil-
ity that it limits AAA development by mechanisms not examined in this study. Further studies are needed to 
substantiate the findings in other populations, including women, and further experimental models. Secondly, 
systemic rhKAL administration was not effective in limiting inflammation unlike transgenic upregulation. This 
could be because rhKAL administration may not be as potent as the effect of transgenic overexpression of KAL 
although this was not specifically confirmed. The most appropriate way to deliver rhKAL to limit AAA needs 
to be further investigated.
In conclusion, this study suggests a protective role of KAL in AAA pathogenesis through limiting inflam-
mation, ECM remodelling, ROS and VSMC apoptosis. The findings suggest that upregulating KAL maybe a 
therapeutic target to limit AAA development and progression.
Figure 4.  KAL attenuated the expression of extracellular matrix regulating genes in VSMCs. VSMCs were 
plated at 1 ×  106 cells/ml in 500 µl DMEM + 5% FBS and allowed to adhere overnight. Subsequently, the cells 
were incubated with 2 nm AngII or AAA thrombus-derived media for 24 h. At the end of the experiment, 
VSMCs were collected in the RNAlater and total RNA isolated to perform quantitative real time PCR (QRT–
PCR). (A,B) Incubating VSMCs with 2 nm AngII resulted in significant upregulation of MMP-9 and VEGF 
gene expressions. Co-incubation with 10 nM rhKAL for 24 h attenuated AngII-induced upregulation of MMP-9 
and VEGF. (C,D) VSMCs exposed to AAA thrombus-derived conditioned medium for 24 h promoted MMP-9 
and VEGF expression. Addition of 10 nM rhKAL to the conditioned media resulted in a significant reduction 
in both MMP-9 and VEGF expressions. All experiments were performed in triplicate (n = 6/group). Analysis 
performed by Kruskal Wallis test and post-hoc analysis and statistical significance shown as *P < 0.05; **P < 0.01. 
AngII, angiotensin II; rhKAL, recombinant human kallistatin; MMP, Matrix metalloproteinase; VEGF, vascular 
endothelial growth factor; VSMC, vascular smooth muscle cell; n.s, non-significant.
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